Analysts Set Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Target Price at $804.70

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) have earned an average recommendation of “Moderate Buy” from the twenty-seven research firms that are presently covering the company, MarketBeat.com reports. Nine analysts have rated the stock with a hold recommendation, sixteen have given a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $811.9565.

REGN has been the subject of a number of research analyst reports. Weiss Ratings restated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a report on Friday, March 27th. Royal Bank Of Canada raised their price objective on shares of Regeneron Pharmaceuticals from $745.00 to $765.00 and gave the stock a “sector perform” rating in a report on Monday, March 2nd. Morgan Stanley raised their price objective on shares of Regeneron Pharmaceuticals from $769.00 to $796.00 and gave the stock an “equal weight” rating in a report on Friday. Oppenheimer restated an “outperform” rating and set a $865.00 price objective (up from $750.00) on shares of Regeneron Pharmaceuticals in a report on Monday, February 2nd. Finally, Evercore raised their price objective on shares of Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the stock an “outperform” rating in a report on Thursday, January 22nd.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN opened at $748.87 on Wednesday. Regeneron Pharmaceuticals has a 52-week low of $476.49 and a 52-week high of $821.11. The company has a 50-day simple moving average of $767.42 and a 200 day simple moving average of $721.06. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.39 and a current ratio of 4.13. The company has a market capitalization of $79.17 billion, a PE ratio of 18.02, a price-to-earnings-growth ratio of 1.99 and a beta of 0.40.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $10.74 by $0.70. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The business had revenue of $3.88 billion during the quarter, compared to the consensus estimate of $3.76 billion. During the same quarter last year, the company posted $12.07 earnings per share. The firm’s quarterly revenue was up 2.5% compared to the same quarter last year. On average, research analysts predict that Regeneron Pharmaceuticals will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 5th. Stockholders of record on Friday, February 20th were given a $0.94 dividend. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. This is an increase from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. The ex-dividend date of this dividend was Friday, February 20th. Regeneron Pharmaceuticals’s payout ratio is presently 9.05%.

Insider Activity

In other news, SVP Jason Pitofsky sold 2,036 shares of the business’s stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $778.52, for a total value of $1,585,066.72. Following the sale, the senior vice president owned 4,272 shares of the company’s stock, valued at $3,325,837.44. The trade was a 32.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Huda Y. Zoghbi sold 1,638 shares of the business’s stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $781.33, for a total transaction of $1,279,818.54. Following the completion of the sale, the director directly owned 1,703 shares in the company, valued at approximately $1,330,604.99. This trade represents a 49.03% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 3,774 shares of company stock valued at $2,942,738 over the last quarter. Company insiders own 7.02% of the company’s stock.

Institutional Trading of Regeneron Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of the business. Purpose Unlimited Inc. bought a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter valued at approximately $87,000. Rockefeller Capital Management L.P. raised its position in shares of Regeneron Pharmaceuticals by 4.7% in the fourth quarter. Rockefeller Capital Management L.P. now owns 27,053 shares of the biopharmaceutical company’s stock valued at $20,882,000 after purchasing an additional 1,211 shares during the period. World Investment Advisors raised its position in shares of Regeneron Pharmaceuticals by 56.5% in the fourth quarter. World Investment Advisors now owns 798 shares of the biopharmaceutical company’s stock valued at $616,000 after purchasing an additional 288 shares during the period. PeakShares LLC bought a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter valued at approximately $1,102,000. Finally, Pure Financial Advisors LLC raised its position in shares of Regeneron Pharmaceuticals by 35.4% in the fourth quarter. Pure Financial Advisors LLC now owns 497 shares of the biopharmaceutical company’s stock valued at $384,000 after purchasing an additional 130 shares during the period. Institutional investors own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.